This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.

Atlas Venture’s Bruce Booth believes the belt-tightening by biotechs in the past few years will presage a better financing outlook for companies, but the ripple effects will be felt for some time to come. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, the longtime biotech VC said that there are clear positive signs for biotech, with the XBI ETF bouncing back from its lows in the 60s, February’s robust follow-on financing market and a stream of M&A deals. “Everybody did belt-tightening the last few years,” said Booth. “So, you’re coming from a good place in terms of overall burn rates, and companies, I think, are in a good place to be financed by the next wave of investors.”

View full story: https://www.biocentury.com/article/651821

#biotech #pharma #biopharma #lifescience #TheBioCenturyShow 

00:00 - Intro
01:54 - Capital Markets
07:19 - How to Pitch a VC
12:12 - Obesity 
16:30 - New Modalities
22:28 - Industry Efficiency, AI